Shan F, Somasundaram A, Bruno T, Workman C, Vignali D
Trends Cancer. 2022; 8(11):944-961.
PMID: 35853825
PMC: 9588644.
DOI: 10.1016/j.trecan.2022.06.008.
Postow M, Goldman D, Shoushtari A, Betof Warner A, Callahan M, Momtaz P
J Clin Oncol. 2021; 40(10):1059-1067.
PMID: 34928709
PMC: 8966970.
DOI: 10.1200/JCO.21.01570.
Duru G, van Egmond M, Heemskerk N
Front Immunol. 2020; 11:584723.
PMID: 33262763
PMC: 7686513.
DOI: 10.3389/fimmu.2020.584723.
Mizuguchi S, Takahama M, Nakajima R, Inoue H, Ito R, Yamamoto R
Biomed Hub. 2020; 4(2):1-5.
PMID: 31993425
PMC: 6985888.
DOI: 10.1159/000501157.
Kageyama S, Yamaguchi S, Ito S, Suehara Y, Saito T, Akaike K
Int Cancer Conf J. 2019; 5(4):192-196.
PMID: 31149453
PMC: 6498278.
DOI: 10.1007/s13691-016-0256-8.
Clinical protein science in translational medicine targeting malignant melanoma.
Gil J, Betancourt L, Pla I, Sanchez A, Appelqvist R, Miliotis T
Cell Biol Toxicol. 2019; 35(4):293-332.
PMID: 30900145
PMC: 6757020.
DOI: 10.1007/s10565-019-09468-6.
Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma.
Ligtenberg M, Pico de Coana Y, Shmushkovich T, Yoshimoto Y, Truxova I, Yang Y
Mol Ther. 2018; 26(6):1482-1493.
PMID: 29735366
PMC: 5986970.
DOI: 10.1016/j.ymthe.2018.04.015.
Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis.
Zhu H, Jia Z, Trush M, Robert Li Y
React Oxyg Species (Apex). 2018; 2(4):308-314.
PMID: 29721548
PMC: 5926243.
DOI: 10.20455/ros.2016.853.
Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg S, Narayan A, Kole A, Decker R, Teysir J, Carriero N
Clin Cancer Res. 2018; 24(8):1872-1880.
PMID: 29330207
PMC: 5899677.
DOI: 10.1158/1078-0432.CCR-17-1341.
Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy.
Tan S, Zhang C, Gao G
Signal Transduct Target Ther. 2017; 1:16029.
PMID: 29263905
PMC: 5661648.
DOI: 10.1038/sigtrans.2016.29.
Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.
Stern P
Ther Adv Vaccines. 2017; 5(3):55-68.
PMID: 28794878
PMC: 5524245.
DOI: 10.1177/2051013617720659.
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
Lohmueller J, Finn O
Pharmacol Ther. 2017; 178:31-47.
PMID: 28322974
PMC: 5600680.
DOI: 10.1016/j.pharmthera.2017.03.008.
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.
Lesterhuis W, Bosco A, Millward M, Small M, Nowak A, Lake R
Nat Rev Drug Discov. 2017; 16(4):264-272.
PMID: 28057932
DOI: 10.1038/nrd.2016.233.
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies.
Tan S, Chen D, Liu K, He M, Song H, Shi Y
Protein Cell. 2016; 7(12):866-877.
PMID: 27815822
PMC: 5205664.
DOI: 10.1007/s13238-016-0337-7.
Tumor lysis syndrome and metastatic melanoma.
Meeks M, Hammami M, Robbins K, Cheng K, Lionberger J
Med Oncol. 2016; 33(12):134.
PMID: 27807723
DOI: 10.1007/s12032-016-0854-5.
Roles of regulatory T cells in cancer immunity.
Takeuchi Y, Nishikawa H
Int Immunol. 2016; 28(8):401-9.
PMID: 27160722
PMC: 4986235.
DOI: 10.1093/intimm/dxw025.
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid.
Beck K, Dong J, Geskin L, Beltrani V, Phelps R, Carvajal R
J Immunother Cancer. 2016; 4:20.
PMID: 27096097
PMC: 4835882.
DOI: 10.1186/s40425-016-0123-3.
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Khalil D, Smith E, Brentjens R, Wolchok J
Nat Rev Clin Oncol. 2016; 13(5):273-90.
PMID: 26977780
PMC: 5551685.
DOI: 10.1038/nrclinonc.2016.25.
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Ettinger D, Wood D, Akerley W, Bazhenova L, Borghaei H, Camidge D
J Natl Compr Canc Netw. 2016; 14(3):255-64.
PMID: 26957612
PMC: 10181272.
DOI: 10.6004/jnccn.2016.0031.
Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout M, Sluijter B, Santegoets S, van Leeuwen P, van den Tol M, van den Eertwegh A
Cancer Immunol Immunother. 2016; 65(4):405-15.
PMID: 26935057
PMC: 4826413.
DOI: 10.1007/s00262-016-1811-z.
